In the nascent world of global pot investing and sourcing, assets can be hard to document — but may hold enormous rewards.

U.S. and Chinese officials are set to begin trade negotiations on Monday in the hope of reaching a deal during a 90-day truce between President Donald Trump and Xi Jinping.

In ways both small and large, businesses are beginning to feel the bite of the government funding impasse that has shuttered nine major departments.

China’s plan to drive down generic drug prices through a centralized bulk procurement program is set to redraw the industry.

For a biopharmaceutical company as large as Pfizer, achieving truly comprehensive supply chain visibility is a mammoth undertaking.

Europe will be a loser should U.S.-China relations deteriorate further, even if some companies stand to benefit.